艾曲泊帕治疗前后慢性免疫性血小板减少症促凝状态的评估——一项前瞻性队列研究
这项前瞻性多中心研究纳入16例开始艾曲泊帕治疗的成人原发免疫性血小板减少症(ITP)患者和33例对照,评估血小板功能与高凝状态。ITP患者基线存在高凝状态,表现为血小板预活化、凝血酶生成潜力增加及因子VIII和血管性血友病因子水平升高。艾曲泊帕治疗进一步增加血浆凝血酶生成潜力,但未改变其他止血参数。
要点
- ITP患者基线呈高凝状态,伴血小板预活化及凝血酶生成潜力增加。
- ITP患者因子VIII中位数217%、血管性血友病因子中位数167%,均高于对照。
- 艾曲泊帕治疗使凝血酶生成潜力进一步增加,校正多重检验后不显著。
核心结论
- 本研究中ITP患者处于高凝状态,伴血小板预活化、凝血酶生成潜力增加及因子VIII和血管性血友病因子水平升高。
- 艾曲泊帕治疗进一步增加血浆凝血酶生成潜力,但未改变其他止血参数。
研究设计与样本
- 前瞻性多中心研究,纳入16例开始艾曲泊帕治疗的成人原发ITP患者和33例对照。
- 在艾曲泊帕治疗开始前及治疗2至3周后,于全血或血浆中测定血小板(再)活性与高凝状态,并与对照比较。
- 采用混合效应模型评估随时间的变化,并对结果进行多重检验校正。
主要发现
- 基线时,与对照相比,ITP患者糖蛋白VI表达更低、活化血小板更多、对激动剂的反应性更低。
- 与对照相比,ITP患者β-血栓球蛋白水平降低、凝血酶生成峰值升高。
- ITP患者因子VIII中位数217%(IQR 174%-272%),血管性血友病因子中位数167%(IQR 109%-198%)。
- 艾曲泊帕治疗使凝血酶生成潜力增加:滞后时间缩短,峰值和内生凝血酶潜力增加。
- 上述变化在校正多重检验后不显著。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Thrombopoietin receptor agonists are frequently used in treating immune thrombocytopenia (ITP) owing to high response rates and good tolerability. ITP is associated with an increased risk of thrombosis. Whether treatment with eltrombopag further increases this risk is controversial. The mechanisms behind the thrombotic risk in ITP are unclear. OBJECTIVES: To assess platelet function and hypercoagulability in patients with ITP and the effect of eltrombopag thereon. METHODS: This prospective multicenter study assessed adult primary patients with ITP who were starting eltrombopag treatment. Platelet (re)activity and hypercoagulability were measured in whole blood or plasma before start and after 2 to 3 weeks of eltrombopag treatment and compared with those of controls. Change over time was assessed by mixed-effects models, and the results were corrected for multiple testing. RESULTS: We included 16 patients and 33 controls. At baseline, patients with ITP exhibited lower expression of glycoprotein VI, more activated platelets, and lower reactivity toward agonists compared with controls. β-Thromboglobulin levels reduced and thrombin generation peak height increased compared with those of controls. In line with this finding, patients with ITP showed high factor VIII (median, 217%; IQR, 174%-272%) and von Willebrand factor levels (median, 167%; IQR, 109%-198%). Eltrombopag treatment increased thrombin generation potential: lag time decreased and peak height and endogeneous thrombin potential increased. The latter changes were not significant after correction for multiple testing. CONCLUSION: Patients with ITP in this study were in a hypercoagulable state, with preactivated platelets, increased thrombin generation potential, and increased levels of factor VIII and von Willebrand factor. Eltrombopag treatment further increased plasma thrombin generation potential but no other hemostatic parameters.
引用
- van Dijk WEM, Poolen GC, Huisman A, et al. Evaluation of the procoagulant state in chronic immune thrombocytopenia before and after eltrombopag treatment-a prospective cohort study. J Thromb Haemost. 2022. PMID: 36696209. doi:10.1016/j.jtha.2022.11.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。